Therapeutic Drug Monitoring
Antieleptics
Gabapentin
Lacosamide
Lamotrigine
Levetiracetam
Oxcarbazepine Metabolite
Topiramate
Zonisamide
ARK Levetiracetam II Assay
The ARK™ Levetiracetam II Assay is a homogeneous enzyme immunoassay intended for the quantitative determination of levetiracetam in human serum or plasma on automated clinical chemistry analyzers. The measurements obtained are used in the monitoring of levetiracetam levels to help ensure appropriate therapy.
Assay Characteristics
- Fast and efficient routine monitoring for Levetiracetam
- Monoclonal antibody guarantees consistent lot-to-lot quality
- Excellent precision, even in trough concentrations
- Liquid, ready-to-use reagents, calibrators, and controls
- On-board stability for at least 60 days
Background
Levetiracetam (KEPPRA®) is an anti-convulsant drug approved for use as an adjunctive therapy in the treatment of epilepsy. It is also indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalization in adults and adolescents from 16 years of age with newly diagnosed epilepsy.
Reference ranges for seizure control have been proposed, encompassing concentrations from 6 to 46 μg/mL (35 to 270 μmol/L) for trough samples. Circulating levels of levetiracetam (serum blood concentrations) may be affected by compliance, renal function, pregnancy, drug-drug interactions, and timing of the sample draw. Furthermore, the clinical effect of these serum blood concentrations may be further altered by changes in disease progression and the addition or withdrawal of concomitant drugs that may interact pharmacodynamically with circulating levels of levetiracetam.